Literature DB >> 24030969

Ocelot catheter for the treatment of long SFA occlusion.

Ian Cawich1, Konstantinos Marmagkiolis, Mehmet Cilingiroglu.   

Abstract

Long saphenous femoral artery (SFA) chronic total occlusions (CTOs) are considered the "Achilles heel" of the lower extremity percutaneous interventions. Antegrade, retrograde, or transcollateral approaches, intraluminal or subintimal techniques with re-entry and specialized CTO devices using microdissection, vibrational energy, and laser have all been tried for the management of such challenging lesions with various success rates. Ocelot is the first CTO crossing device using real-time OCT technology. Its crossing catheter utilizes spiral wedges to corkscrew the CTO cap, while real-time OCT offers direct visualization to facilitate intravascular true-lumen orientation. The recently presented results of the CONNECT-II study demonstrated crossing success of 97% and freedom from major adverse events of 98%. We present one of the most challenging SFA CTOs with ambiguous proximal cap in the ostium of the SFA, heavy calcification and involving almost the entire length of the SFA. The Ocelot catheter assisted to the successful true-lumen recanalization of that complex lesion.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  chronic total occlusion; peripheral arterial disease; peripheral intervention; peripheral transluminal angioplasty

Mesh:

Year:  2013        PMID: 24030969     DOI: 10.1002/ccd.25187

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  2 in total

1.  The use of crossing catheters in the recanalization of below-the-knee chronic total occlusions in patients with critical limb ischemia.

Authors:  Burak Teymen; Mehmet Özkan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-07-03       Impact factor: 0.332

2.  Five-year outcomes after revascularization of superficial femoral artery occlusion using Ocelot catheter.

Authors:  Przemysław Nowakowski; Piotr Buszman; Adam Janas; Stefan Kiesz; Pawel Buszman
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-12-08       Impact factor: 1.426

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.